| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $4.2M | +3.0% |
| SG&A Expense | $6.8M | +90.3% |
| Operating Income | -$11.0M | -43.6% |
| Net Income | -$10.7M | -27.5% |
| EPS (Basic) | -$8.73 | -1308.1% |
| EPS (Diluted) | -$8.73 | -1308.1% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $10.0M | +19.0% |
| Current Assets | $10.1M | +19.1% |
| Total Assets | $10.1M | +18.8% |
| Current Liabilities | $2.7M | +224.6% |
| Total Liabilities | $2.7M | +224.6% |
| Stockholders' Equity | $7.4M | -3.3% |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$7.4M | -108.4% |
| Capital Expenditures | $7K | +100.9% |
| Investing Cash Flow | -$7K | -100.9% |
| Financing Cash Flow | $9.0M | -24.6% |
| Free Cash Flow | -$7.4M | -108.4% |